King & Wood Mallesons (KWM) advised Sino Biopharmaceutical Limited (Sino Biopharmaceutical, SEHK Stock Code: 1177) on its first-time issuance of €750 million zero coupon convertible bonds due 2025. Citigroup Global Markets Limited, The Hongkong and Shanghai Banking Corporation Limited, UBS AG Hong Kong Branch, J.P. Morgan Securities Plc and Goldman Sachs (Asia) L.L.C. were the joint global coordinators, joint bookrunners and joint lead managers of the transaction. The convertible bonds were listed on Hong Kong Stock Exchange.
Sino Biopharmaceutical is a leading, innovative and research and development driven pharmaceutical conglomerate in the PRC. It was selected as a constituent stock of the Hang Seng Index in 2018 and a constituent stock of the Hang Seng China Enterprises Index in 2019.
KWM acted for Sino Biopharmaceutical in respect of Hong Kong, English and PRC laws. The team was led by Hong Kong partners Ng Ching-wo, Sheldon Tse, Richard Mazzochi and Shanghai partner Liu Dongya. The team was supported by counsel Ian Hardee and Sheryl Cheung, senior associate Eric Lo, and associates Stefy Tong, Christine Lau, Katherine Yang, Evangeline Chee and Wang Xiaowei.
*Any reference to “Hong Kong” or “Hong Kong SAR” shall be construed as a reference to “Hong Kong Special Administrative Region of the People’s Republic of China”.